Supplementary Figure 3.

**A**

![Graph showing live cells (% of ctrl) vs. BKT140 (µM) and Rituximab (µg/ml)]

**B**

![Flow cytometry plots of BL-2 and Raji cells showing activated caspase 3] (ctrl + BKT 8, ctrl + BKT 20)

**C**

![Flow cytometry plots of BL-2 and BJAB cells showing caspase-3 activation in the absence or presence of BKT140 (8 µM or 20 µM) for 48 hours]

**Apoptosis induced by BKT140 and Rituximab.**

(A) Jurkat cells were treated with BKT140 (8 or 20 µM), rituximab (100 µg/ml) or combination of both for 48 hours, viability was determined using PI exclusion. (B) Caspase-3 activation in BL-2 and Raji cells incubated in the absence or presence of BKT140 (8 µM or 20 µM) for 48 hours. (C) Mitochondrial membrane potential (ΔΨm) in NHL cells, treated with BKT140, rituximab or combination of both agents for 12 hours was determined by flow cytometry using DiOC6 staining.